United Therapeutics' Tyvaso Outlook Faces Near-Term Pressure After Liquidia Settlement, RBC Says
RBC analysts noted that United Therapeutics' outlook for its Tyvaso product faces near-term pressure following a settlement agreement with Liquidia.
Stocks · News reference
Liquidia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026
Liquidia Corporation announced it will release its third quarter 2026 financial results on November 10, 2026, followed by a live webcast to discuss the results and provide a corporate update.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Maintains Buy on Liquidia, Raises Price Target to $65
HC Wainwright & Co. analyst Andrew S. Fein maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price target from $58 to $65.
Nasdaq Dips Over 400 Points; Bank of America Shares Tumble After Q3 Results
US stocks fell Wednesday as Nasdaq dropped 1.54% and Dow 0.35%; Bank of America sank 5% after weak results, while oil rose and inflation topped forecasts.
Wells Fargo Maintains Equal-Weight on Liquidia, Raises Price Target to $33
Wells Fargo analyst Benjamin Burnett maintains Liquidia (NASDAQ:LQDA) with a Equal-Weight and raises the price target from $30 to $33.
Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mostly fell, but Bending Spoons surged 40% after Berkshire’s $330M investment. Liquidia and Verastem also posted strong gains.
This Albemarle Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Analysts upgraded ALB, LQDA, WY, RAL, setting or revising price targets to $130, $70, $25, $88.